Abstract:Peptides are considered as potent therapeutic drugs primarily due to the exquisite potency and selectivity to targets. However, the development and clinical application of peptide drugs were severely limited by the poor in vivo lifespans. Here, we designed an improved small albumin-binding polypeptide that can associate with human serum albumin (HSA) and liberate the bioactive peptide. Using glucagon-like peptide-1 (GLP-1) as a model, two new long-lasting GLP-1 analogs (termed XTS1 and XTS2) containing an albumin-binding domain, a protease-cleavable linker and a mutated GLP-1(A8Aib) were designed to demonstrate the sustained release of GLP-1 due to the plasma thrombin (TBN) digestion. Two XTS peptides were prepared of high purity (>99%) and accurate molecular weight determined by reversed high-performance liquid chromatography and mass spectrometry, respectively. In vitro measurements of surface plasmon resonance indicated that XTS1 associate with serum albumins of all species with higher affinity compared with XTS2. Metabolic stability of XTS1 in vitro in human plasma was also better than that of XTS2. Protease cleavage assay results of XTS peptides demonstrated the controlled-release of transient GLP-1 from the XTS1 and XTS2 mixture after thrombin-catalyzed hydrolysis. Then the intraperitoneal glucose tolerance test (IPGTT) showed that the glucose-lowering efficacies of XTS1 were in a dosage-dependent manner within the range of 0.1-0.9 mg kg-1. In addition, XTS1 showed similar hypoglycemic intensity and significantly longer action duration compared to Liraglutide in both multiple IPGTTs and hypoglycemic duration test. Apparently extended plasma half-lives of ∼2.3 and ∼3.5 days were observed after a single subcutaneous administration of XTS1 (0.9 mg kg-1) in rats and cynomolgus monkeys, respectively. Furthermore, twice-weekly subcutaneously dosed XTS1 in db/db mice achieved long-term beneficial effects on body weight, hemoglobin A1C (HbA1C) lowering and the function of pancreatic beta cells. These studies support that XTS1 exerts potential as a therapeutic drug for the treatment of T2DM.

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Engineering an Enhanced Thrombin-Based GLP-1 Analog with Long-Lasting Glucose-Lowering and Efficient Weight Reduction.

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Novel Fatty Chain-Modified Glucagon-Like Peptide-1 Conjugates with Enhanced Stability and Prolonged in Vivo Activity.

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid

Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

Novel Fatty Acid Chain Modified GLP-1 Derivatives with Prolonged in Vivo Glucose-Lowering Ability and Balanced Glucoregulatory Activity.

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-like Peptide-1 Conjugates.

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

A New GLP-1 Analogue with Prolonged Glucose-Lowering Activity in Vivo Via Backbone-Based Modification at the N-terminus

Long-acting release microspheres containing novel GLP-1 analog as an antidiabetic system.

Novel Coumarin Modified Glp-1 Derivatives With Enhanced Plasma Stability And Prolonged In Vivo Glucose-Lowering Ability

Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogs

A novel GLP-1 analog, a dimer of GLP-1 via covalent linkage by a lysine, prolongs the action of GLP-1 in the treatment of type 2 diabetes

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.

PGLP-1, a Novel Long-Acting Dual-Function GLP-1 Analog, Ameliorates Streptozotocin-Induced Hyperglycemia and Inhibits Body Weight Loss.